We have recently reported a discovery of novel potent inhibitors of influenza M1 matrix protein. The matrix protein structurally forms the protein envelope and has no close human analogues. That’s why the newly identified compounds hold promise of both high potency and low toxicity. The best of the compounds were tested in-vivo in lethal model of influenza in mice. The results of the test are summarized on the graph below.
The horizontal axis spans the time since the beginning of the experiment. The surviving fraction (the vertical axis) to the date exhibits the protection properties of the tested compound (F10). The positive control was provided by the well known drug, Rimantadine. The control group dies off completely by the day nine.
The protection of the animals by f10 is substantial and dose-dependent. We achieved about 60% protection level at dose 22.5mg/kg. There was no signs of toxicity at this dose.
The presented results are the first ever demonstrations of efficacy of virus matrix proteins inhibitors in-vivo. F10 is more effective in vivo in mice than Rimantadine.
- New MA/p17 matrix protein inhibitors display broad antiviral activity against multiple subtypes of HIV-1
- MA/p17 HIV matrix protein is a promising target for drug discovery
- Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo
- Beefing up the pipeline: new leads against influenza virus identified
- Do we need those nM-inhibitors?